Wednesday, July 8, 2026

Drug profile · INN

perfluorohexyloctane

perfluorohexyloctane (NOVATEARS) is a unknown. Associated with Lacuna Pharma Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved TGA: approved
US status approved
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — perfluorohexyloctane
US status
approved
Class
Route
OPHTHALMIC
Patents
0
Programs
4
Data quality
0.84

Quick answer

perfluorohexyloctane (NOVATEARS) is a unknown. Associated with Lacuna Pharma Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN perfluorohexyloctane
Brand NOVATEARS
Mechanism Unknown
Route OPHTHALMIC
Formulation SOLUTION/DROPS

Mechanism of action

Unknown

Approval history

Authority Status Date
FDA approved
TGA approved

Pipeline programs

  1. Ear pills Phase 3 · Universal Integrated · Intradialytic Hypotension
  2. MIE Phase 3 · Chinese Academy of · Esophageal Carcinoma
  3. MIE Phase 2 · First People's Hospital · Esophageal Cancer
  4. TEA plus GDMT Unknown · First People's Hospital · Heart Failure With Reduced Ejection Fraction

Frequently asked questions

What is perfluorohexyloctane?

perfluorohexyloctane (NOVATEARS) is a unknown. Associated with Lacuna Pharma Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for perfluorohexyloctane?

NOVATEARS is a marketed brand name for perfluorohexyloctane. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of perfluorohexyloctane?

perfluorohexyloctane has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.